Comprehensive Analysis of NAFLD and the Therapeutic Target Identified

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Oct 7

PMID 34616724

Citations 16

Authors

Weiheng Wen

Peili Wu

Yugang Zhang

Zijian Chen

Jia Sun

Hong Chen

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a serious health threat worldwide. The aim of this study was to comprehensively describe the metabolic and immunologic characteristics of NAFLD, and to explore potential therapeutic drug targets for NAFLD. Six NAFLD datasets were downloaded from the Gene Expression Omnibus (GEO) database, including GSE48452, GSE63067, GSE66676, GSE89632, GSE24807, and GSE37031. The datasets we then used to identify and analyze genes that were differentially expressed in samples from patients with NAFLD and normal subjects, followed by analysis of the metabolic and immunologic characteristics of patients with NAFLD. We also identified potential therapeutic drugs for NAFLD using the Connectivity Map (CMAP) database. Moreover, we constructed a prediction model using minimum depth random forest analysis and screened for potential therapeutic targets. Finally, therapeutic targets were verified in a fatty liver model stimulated by palmitic acid (PA). A total of 1,358 differentially expressed genes (DEGs) were obtained, which were mainly enriched in carbohydrate metabolism, lipid metabolism, and other metabolic pathways. Immune infiltration analysis showed that memory B cells, regulatory T cells and M1 macrophage were significantly up-regulated, while T cells follicular helper were down regulated in NAFLD. These may provide a reference for the immune-metabolism interaction in the pathogenesis of NAFLD. Digoxin and helveticoside were identified as potential therapeutic drugs for NAFLD via the CMAP database. In addition, a five-gene prediction model based on minimum depth random forest analysis was constructed, and the receiver operating characteristic (ROC) curves of both training and validation set reached 1. The five candidate therapeutic targets were ENO3, CXCL10, INHBE, LRRC31, and OPTN. Moreover, the efficiency of hepatocyte adipogenesis decreased after OPTN knockout, confirming the potential use of OPTN as a new therapeutic target for NAFLD. This study provides a deeper insight into the molecular pathogenesis of NAFLD. We used five key genes to construct a diagnostic model with a strong predictive effect. Therefore, these five key genes may play an important role in the diagnosis and treatment of NAFLD, particularly those with increased OPTN expression.

Citing Articles

Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework.

Wang S, Zhang R, Guo P, Yang H, Liu Y, Zhu H EPMA J. 2025; 16(1):183-197.

PMID: 39991098 PMC: 11842653. DOI: 10.1007/s13167-025-00398-4.

Multiple Machine Learning Identifies Key Gene PHLDA1 Suppressing NAFLD Progression.

Yang Z, Chen Z, Wang J, Li Y, Zhang H, Xiang Y Inflammation. 2024; .

PMID: 39496918 DOI: 10.1007/s10753-024-02164-6.

Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver disease.

Zhu Q, Liu J, Mei W, Zeng C Biochem Biophys Rep. 2024; 40:101829.

PMID: 39376593 PMC: 11456910. DOI: 10.1016/j.bbrep.2024.101829.

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives.

Yan M, Man S, Ma L, Guo L, Huang L, Gao W Clin Mol Hepatol. 2024; 30(4):620-648.

PMID: 38988278 PMC: 11540396. DOI: 10.3350/cmh.2024.0315.

Identifying metabolic dysfunction-associated steatotic liver disease in patients with hypertension and pre-hypertension: An interpretable machine learning approach.

Chen C, Zhang W, Yan G, Tang C Digit Health. 2024; 10:20552076241233135.

PMID: 38389508 PMC: 10883118. DOI: 10.1177/20552076241233135.

References

Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul M, Iannelli A . Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010; 5(10):e13577. PMC: 2962651. DOI: 10.1371/journal.pone.0013577. View

Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S . Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011; 10:49. PMC: 3088890. DOI: 10.1186/1476-511X-10-49. View

Gomes A, Teijeiro A, Buren S, Tummala K, Yilmaz M, Waisman A . Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma. Cancer Cell. 2016; 30(1):161-175. DOI: 10.1016/j.ccell.2016.05.020. View

Cortez-Pinto H, Chatham J, Chacko V, Arnold C, Rashid A, Diehl A . Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999; 282(17):1659-64. DOI: 10.1001/jama.282.17.1659. View

Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J . Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis. 2003; 24(11):1801-9. DOI: 10.1093/carcin/bgg154. View

Tomita K, Freeman B, Bronk S, LeBrasseur N, White T, Hirsova P . CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep. 2016; 6:28786. PMC: 4923862. DOI: 10.1038/srep28786. View

Van Herck M, Weyler J, Kwanten W, Dirinck E, De Winter B, Francque S . The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Front Immunol. 2019; 10:82. PMC: 6372559. DOI: 10.3389/fimmu.2019.00082. View

Soderberg C, Marmur J, Eckes K, Glaumann H, Sallberg M, Frelin L . Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. APMIS. 2011; 119(7):412-20. DOI: 10.1111/j.1600-0463.2011.02746.x. View

Quiroga A, Comanzo C, Heit Barbini F, Lucci A, Vera M, Lorenzetti F . IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice. Toxicol Appl Pharmacol. 2019; 379:114650. DOI: 10.1016/j.taap.2019.114650. View

10.

Zhang Y, Li C, Yao G, Du L, Liu Y, Zheng X . Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway. Diabetes. 2017; 66(6):1535-1547. PMC: 5860190. DOI: 10.2337/db16-1354. View

11.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

12.

Jia W, Wei M, Rajani C, Zheng X . Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 2020; 12(5):411-425. PMC: 8106556. DOI: 10.1007/s13238-020-00804-9. View

13.

Desert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S . Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology. 2017; 66(5):1502-1518. DOI: 10.1002/hep.29254. View

14.

Assuncao S, Sorte N, Alves C, Mendes P, Alves C, Silva L . Inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD) in obese children and adolescents. Nutr Hosp. 2018; 35(1):78-83. DOI: 10.20960/nh.1317. View

15.

Ouyang X, Han S, Zhang J, Dioletis E, Nemeth B, Pacher P . Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metab. 2018; 27(2):339-350.e3. PMC: 5806149. DOI: 10.1016/j.cmet.2018.01.007. View

16.

Codd V, Mangino M, van der Harst P, Braund P, Kaiser M, Beveridge A . Common variants near TERC are associated with mean telomere length. Nat Genet. 2010; 42(3):197-9. PMC: 3773906. DOI: 10.1038/ng.532. View

17.

Allan M, Potts J, Pomp D . Comparative mapping of RPL3, a gene overexpressed in multiple obesity models. Anim Biotechnol. 2002; 12(2):167-71. DOI: 10.1081/ABIO-100108343. View

18.

Zhang X, Wu W, Xu W, Man K, Wang X, Han J . C-X-C Motif Chemokine 10 Impairs Autophagy and Autolysosome Formation in Non-alcoholic Steatohepatitis. Theranostics. 2017; 7(11):2822-2836. PMC: 5562218. DOI: 10.7150/thno.19068. View

19.

Roberts M, Young I, Trouton T, Trimble E, Khan M, Webb S . Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet. 1990; 336(8708):143-5. DOI: 10.1016/0140-6736(90)91661-s. View

20.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View